GlassScriptPhysician profile
Kasra S Kaghazchi
NPI 1811391097
$5,287.81
in general payments reported to CMS, 2019-2025
14 companies · $394 in 2025
The $394 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,519 · 2020: $672 · 2021: $571 · 2022: $714 · 2023: $731 · 2024: $687 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,811.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $3,845.95 | 2019-2025 | Collagenase Santyl, Regranex, Oasis |
| Kerecis Limited | $350.32 | 2019-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Misonix INC | $238.09 | 2019-2020 | |
| Osiris Therapeutics INC. | $224.48 | 2019 | |
| Organogenesis INC. | $125.24 | 2021-2022 | |
| Crossroads Extremity Systems, LLC | $108.10 | 2019 | |
| Zimmer Biomet Holdings, INC. | $84.49 | 2020 | |
| Stryker Corporation | $76.44 | 2024 | Salvation |
| Medela LLC | $53.56 | 2019 | |
| Integra Lifesciences Corporation | $42.59 | 2022-2023 | Tenoglide |
| Convatec INC. | $42.50 | 2024 | |
| Paratek Pharmaceuticals, INC. | $37.99 | 2022-2023 | Nuzyra |
| Wright Medical Technology, INC. | $32.48 | 2020 | |
| Kci USA, INC. | $25.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kasra Kaghazchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.